Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-07934040 + pembrolizumab
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
PF-07934040 + pembrolizumab is a combination therapy under investigation for the treatment of advanced solid tumors harboring mutations in the KRAS gene. **PF-07934040** is an orally administered small molecule inhibitor that targets mutant KRAS, aiming to induce apoptosis and inhibit proliferation in tumor cells carrying these mutations. **Pembrolizumab** is a monoclonal antibody immune checkpoint inhibitor that blocks PD-1, enhancing T-cell mediated anti-tumor activity. The combination is in phase 1 clinical trials for cancers such as pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer with KRAS mutations. PF-07934040 is developed by Pfizer, and pembrolizumab by Merck.
- Other names
- PembroLambrolizumab
02
Targets
KRAS (Kirsten rat sarcoma viral oncogene homolog)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on PF-07934040 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-07934040 + pembrolizumab.